AstraZeneca could supply potential coronavirus vaccine from September

Epoch Times

Early positive results from a phase one trial of the candidate included all 45 participants producing antibodies and eight volunteers producing neutralizing antibodies, which bind to the CCP (Chinese Communist Party) virus.

Scientists are now expanding the trials to include adults aged over 70, and a small number of children.

"When you're developing a vaccine, there's always landmines and traps along the way to get in the way of a successful completion of developing a safe and effective vaccine", Fauci said late Thursday.

Known as hyperimmune globulin, those products are "where the first real treatments are going to be", he said, predicting success also with research into monoclonal antibodies that home in on and neutralize the ability of the virus to enter human cells.

"If we focus on people who maybe are at higher risk of exposure to coronavirus we'll get a signal of whether or not the vaccine is working sooner", Dr Duncan said.

Oxford University and AstraZeneca plan to recruit around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine which on Thursday received United States backing worth up to US$1.2 billion (S$1.71 billion). "That's the reason why I am cautiously optimistic about it".

Fauci, who heads the National Institute of Allergy and Infectious Diseases, an office inside the National Institutes of Health, was speaking during a CNN town hall. "We need to be urgently exploring other vaccine candidates".

Epoch Times

Companies that pass phase one trials, including Oxford and Moderna, will shift to massive phase two trials rather than the small trials that are typical.

Fauci called Moderna's vaccine data "quite promising" and "better than we thought" in an interview with NPR on Friday morning. NIAID plans to submit the data to a journal for peer review.

"I said it would likely be between a year and 18 months before we would have a vaccine; I think that schedule is still intact", Fauci said.

The US Department of Health will dole out $1.2 billion for 300 million doses of the vaccine, which is being created in conjunction with the University of Oxford.

Inovio's IN0-4800 candidate targets the major surface antigen Spike protein of the CCP virus, which causes the COVID-19 disease.

The China-based company said it has received $15 million in funding from two investors that will help speed up development of the vaccine, dubbed CoronaVac.

A number of efforts to develop a coronavirus vaccine are underway around the world.



Other news